Bavarian Nordic — November 2019
-
-
Rigtig
fin nyhed: BAVA tager vaccine-salgs-topmanden fra GSK - Jean-Christophe May, Global Vaccines Commercialization Leader - samtidigt med vaccinerne. Han må være en af dem, der ved mest om vaccinerne og hvordan man bør gribe (intensiveret) markedsføring an. -
-
Blot en lille servicemeddelse om at man kan møde Bavarian ved selvsyn d. 21. november og stille spørgsmål. https://www.eventbrite.co.uk/e/kapitalmarkedseftermiddag-2111-2019-nu-med-astralis-ogsa-tickets-79684958857
-
Podcast med Zealand: https://www.proinvestor.com/index.php?p=debat_1&postid=79181
-
-
Zealand Pharma completes Phase 3 clinical program for HypoPal
rescue pen, initiates a new Phase 2 clinical proof of concept trial with dasiglucagon, and secures DKK 560 million in additional investment -
Sikke en nyhed lige inden regnskab
-
Financial results for the first nine months of 2019
Revenue DKK 29.8 million / USD 4.4 million (DKK 24.9 million / USD 3.9 million in the first nine months of 2018).
Net operating expenses DKK 431.5 million / USD 62.9 million (DKK 330.6 million / USD 51.3 million in the first nine months of 2018).
Net operating result DKK –402.1 million / USD –58.7 million (DKK 797.5 million / USD 123.8 million in the first nine months of 2018).
Cash including marketable securities amounted to DKK 1,543.2 milli -
Ny Zealand Pharma-direktør: Endelig forstår markedet vores værdi - vi får stor opmærksomhed fra amerikanske investorer:
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind